923
Views
30
CrossRef citations to date
0
Altmetric
Research Paper

Genetic disruption of USP9X sensitizes colorectal cancer cells to 5-fluorouracil

, &
Pages 1319-1324 | Received 27 Jul 2012, Accepted 08 Aug 2012, Published online: 16 Aug 2012

References

  • Letai AG. Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. Nat Rev Cancer 2008; 8:121 - 32; http://dx.doi.org/10.1038/nrc2297; PMID: 18202696
  • Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010; 463:103 - 7; http://dx.doi.org/10.1038/nature08646; PMID: 20023629
  • Grasso D, Ropolo A, Lo Ré A, Boggio V, Molejón MI, Iovanna JL, et al. Zymophagy, a novel selective autophagy pathway mediated by VMP1-USP9x-p62, prevents pancreatic cell death. J Biol Chem 2011; 286:8308 - 24; http://dx.doi.org/10.1074/jbc.M110.197301; PMID: 21173155
  • Mouchantaf R, Azakir BA, McPherson PS, Millard SM, Wood SA, Angers A. The ubiquitin ligase itch is auto-ubiquitylated in vivo and in vitro but is protected from degradation by interacting with the deubiquitylating enzyme FAM/USP9X. J Biol Chem 2006; 281:38738 - 47; http://dx.doi.org/10.1074/jbc.M605959200; PMID: 17038327
  • Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 2008; 14:10 - 21; http://dx.doi.org/10.1016/j.ccr.2008.06.001; PMID: 18598940
  • Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271:350 - 3; http://dx.doi.org/10.1126/science.271.5247.350; PMID: 8553070
  • Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 2009; 136:123 - 35; http://dx.doi.org/10.1016/j.cell.2008.10.051; PMID: 19135894
  • Vucic D, Dixit VM, Wertz IE. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 2011; 12:439 - 52; http://dx.doi.org/10.1038/nrm3143; PMID: 21697901
  • Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, et al, Australian Pancreatic Cancer Genome Initiative. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012; 486:266 - 70; PMID: 22699621
  • Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386:623 - 7; http://dx.doi.org/10.1038/386623a0; PMID: 9121588
  • Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104:263 - 9; http://dx.doi.org/10.1172/JCI6863; PMID: 10430607
  • Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, et al. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 2001; 7:1111 - 7; http://dx.doi.org/10.1038/nm1001-1111; PMID: 11590433
  • Kim JS, Crooks H, Foxworth A, Waldman T. Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol Cancer Ther 2002; 1:1355 - 9; PMID: 12516970
  • Wilsker D, Bunz F. Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival. Mol Cancer Ther 2007; 6:1406 - 13; http://dx.doi.org/10.1158/1535-7163.MCT-06-0679; PMID: 17431119
  • Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr., Kinzler KW, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 2009; 106:3964 - 9; http://dx.doi.org/10.1073/pnas.0813333106; PMID: 19225112
  • Sangster-Guity N, Conrad BH, Papadopoulos N, Bunz F. ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene 2011; 30:2526 - 33; http://dx.doi.org/10.1038/onc.2010.624; PMID: 21258400
  • Karakas B, Weeraratna AT, Abukhdeir AM, Konishi H, Gustin JP, Vitolo MI, et al. P21 gene knock down does not identify genetic effectors seen with gene knock out. Cancer Biol Ther 2007; 6:1025 - 30; http://dx.doi.org/10.4161/cbt.6.7.4202; PMID: 17611398
  • Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004; 428:77 - 81; http://dx.doi.org/10.1038/nature02313; PMID: 14999283
  • Papageorgis P, Cheng K, Ozturk S, Gong Y, Lambert AW, Abdolmaleky HM, et al. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res 2011; 71:998 - 1008; http://dx.doi.org/10.1158/0008-5472.CAN-09-3269; PMID: 21245094
  • Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al, Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817 - 25; http://dx.doi.org/10.1056/NEJMoa1011923; PMID: 21561347
  • Topaloglu O, Hurley PJ, Yildirim O, Civin CI, Bunz F. Improved methods for the generation of human gene knockout and knockin cell lines. Nucleic Acids Res 2005; 33:e158; http://dx.doi.org/10.1093/nar/gni160; PMID: 16214806
  • Rago C, Vogelstein B, Bunz F. Genetic knockouts and knockins in human somatic cells. Nat Protoc 2007; 2:2734 - 46; http://dx.doi.org/10.1038/nprot.2007.408; PMID: 18007609

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.